Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.
van der Wiel AMA, Jackson-Patel V, Niemans R, Yaromina A, Liu E, Marcus D, Mowday AM, Lieuwes NG, Biemans R, Lin X, Fu Z, Kumara S, Jochems A, Ashoorzadeh A, Anderson RF, Hicks KO, Bull MR, Abbattista MR, Guise CP, Deschoemaeker S, Thiolloy S, Heyerick A, Solivio MJ, Balbo S, Smaill JB, Theys J, Dubois LJ, Patterson AV, Lambin P. van der Wiel AMA, et al. Among authors: ashoorzadeh a. Mol Cancer Ther. 2021 Dec;20(12):2372-2383. doi: 10.1158/1535-7163.MCT-21-0406. Epub 2021 Oct 8. Mol Cancer Ther. 2021. PMID: 34625504 Free PMC article.
Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
Prosser GA, Copp JN, Mowday AM, Guise CP, Syddall SP, Williams EM, Horvat CN, Swe PM, Ashoorzadeh A, Denny WA, Smaill JB, Patterson AV, Ackerley DF. Prosser GA, et al. Among authors: ashoorzadeh a. Biochem Pharmacol. 2013 Apr 15;85(8):1091-103. doi: 10.1016/j.bcp.2013.01.029. Epub 2013 Feb 8. Biochem Pharmacol. 2013. PMID: 23399641
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP, Mowday AM, Ashoorzadeh A, Yuan R, Lin WH, Wu DH, Smaill JB, Patterson AV, Ding K. Guise CP, et al. Among authors: ashoorzadeh a. Chin J Cancer. 2014 Feb;33(2):80-6. doi: 10.5732/cjc.012.10285. Epub 2013 Jul 12. Chin J Cancer. 2014. PMID: 23845143 Free PMC article. Review.
Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM, Ashoorzadeh A, Williams EM, Copp JN, Silva S, Bull MR, Abbattista MR, Anderson RF, Flanagan JU, Guise CP, Ackerley DF, Smaill JB, Patterson AV. Mowday AM, et al. Among authors: ashoorzadeh a. Biochem Pharmacol. 2016 Sep 15;116:176-87. doi: 10.1016/j.bcp.2016.07.015. Epub 2016 Jul 22. Biochem Pharmacol. 2016. PMID: 27453434
2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
Li X, Guise CP, Taghipouran R, Yosaatmadja Y, Ashoorzadeh A, Paik WK, Squire CJ, Jiang S, Luo J, Xu Y, Tu ZC, Lu X, Ren X, Patterson AV, Smaill JB, Ding K. Li X, et al. Among authors: ashoorzadeh a. Eur J Med Chem. 2017 Jul 28;135:531-543. doi: 10.1016/j.ejmech.2017.04.049. Epub 2017 Apr 22. Eur J Med Chem. 2017. PMID: 28521156
Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug Therapy.
Williams EM, Rich MH, Mowday AM, Ashoorzadeh A, Copp JN, Guise CP, Anderson RF, Flanagan JU, Smaill JB, Patterson AV, Ackerley DF. Williams EM, et al. Among authors: ashoorzadeh a. Biochemistry. 2019 Sep 3;58(35):3700-3710. doi: 10.1021/acs.biochem.9b00376. Epub 2019 Aug 20. Biochemistry. 2019. PMID: 31403283
20 results